Investors and Media
Press Release Details
Arvinas Appoints Ronald Peck, M.D. as Chief Medical Officer
“Dr. Peck arrives at the right time for our company, as we advance ARV-110 through a Phase 1 clinical trial and expect to initiate a Phase 1 clinical trial of ARV-471 in the third quarter of 2019,” said
“Arvinas is leading the industry with its new and exciting technology platform of PROTAC® targeted protein degraders,” said Dr. Peck. “The company has tremendous momentum. With one clinical program, which also received Fast Track designation from
Prior to his work at Tesaro, Dr. Peck served as the CMO of
About PROTAC® Protein Degraders
Arvinas’ PROTAC® protein degraders harness the body’s own natural protein disposal system to degrade disease-causing proteins. PROTAC® protein degraders recruit an E3 ligase to tag the target protein with ubiquitin, which directs its degradation through the proteasome, a large protein complex that breaks down the ubiquitinated target protein into small peptides and amino acids. As the target protein is degraded, the PROTAC® protein degrader is released and acts iteratively to destroy additional target protein.
PROTAC® protein degraders offer numerous potential advantages as therapeutics, including broad tissue distribution, routes of administration that include oral delivery, and simpler manufacturing than other new modalities, such as cell-based therapies.
Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary technology platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. The company’s lead program, ARV-110 for the treatment of patients with metastatic castrate-resistant prostate cancer, began a Phase 1 clinical trial in the first quarter of 2019. The Investigational New Drug application (IND) for ARV-471, in development for the treatment of patients with locally advanced or metastatic ER positive / HER2 negative breast cancer, was cleared by the U.S. Food and Drug Administration (
This press release contains forward-looking statements that involve substantial risks and uncertainties, including statements regarding the development, regulatory status and therapeutic potential of our product candidates. All statements, other than statements of historical facts, contained in this press release, including statements regarding our strategy, future operations, prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make as a result of various risks and uncertainties, including but not limited to the important factors discussed in the “Risk Factors” sections contained in our quarterly and annual reports on file with the Securities and Exchange Commission. The forward-looking statements contained in this press release reflect our current views with respect to future events, and we assume no obligation to update any forward-looking statements except as required by applicable law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this release.
Will O’Connor, Stern Investor Relations
Source: Arvinas Inc.